51 infectious disease mRNA vaccines:

51 infectious disease mRNA vaccines are currently in development.

Moderna (14)

mRNA-1018 — pandemic flu — Phase 3
mRNA-1403 — norovirus — Phase 3
mRNA-1405 — norovirus — Phase 2
mRNA-1345 — pediatric RSV — Phase 2
mRNA-1647 — CMV — Phase 2
mRNA-1189 — EBV (mono) — Phase 2
mRNA-1195 — EBV (long-term sequelae) — Phase 2
mRNA-1975 — Lyme — Phase 2
mRNA-1982 — Lyme — Phase 2
mRNA-1769 — mpox — Phase 2
mRNA-1365 — RSV + hMPV — Phase 1
mRNA-1645 — HIV — Phase 1
mRNA-1215 — Nipah — Phase 1
mRNA-1469 — Bundibugyo ebolavirus — Phase 1

BioNTech / Pfizer (7)
BNT162 + BNT161 — COVID + flu combo
BNT163 — HSV
BNT164 — tuberculosis
BNT165 — malaria
BNT166 — mpox
BNT351 — HIV

Pfizer modRNA flu (PF-07252220), Phase 3
GSK (4)
GSK4382276 / FLUm3HA.b-3NA, Phase 3
GSK4396687 — 2nd-generation COVID19, Phase 1/2
GSK5536522 — pandemic H5N1 flu, Phase 1/2
Flu + COVID combination, Phase 1/2
Arcturus (saRNA) (2)
ARCT-2138 (LUNAR-FLU) - seasonal flu, Phase 1
ARCT-2304 (LUNAR-H5N1)- pandemic H5N1, Phase 1
Sanofi (1)

mRNA acne vaccine (C. acnes) - Phase 1/2
CSPC (5)
SYS6006 — COVID-19, Phase 2
SYS-6017 — herpes zoster, China trial clearance
SYS-6052 — herpes zoster, FDA IND
SYS-6037 — mpox, FDA IND
SYS-6057 — RSV, China trial clearance (mRNA not confirmed)
Walvax / Abogen (4)
RSV mRNA vaccine — clinical-trial approval
Herpes zoster mRNA vaccine — clinical-trial approval
ABO1009-DP — Omicron COVID, Phase 1
ARCoV — COVID, Phase 3
Other, including self-amplifying (14)
CanSino CTP-NCVM — COVID — Phase 2
AIM LVRNA009 — COVID — Phase 3
Daiichi Sankyo DS-5670 — COVID — Phase 1/2
Stemirna SWC002 — COVID — Phase 1/2
EyeGene EG-COVID — COVID — Phase 1/2
HDT Bio HDT-301 — saRNA COVID — Phase 1–2
RVAC RVM-V001 — COVID — Phase 1
RNAimmune RV-1770 — RSV — Phase 1
RNAimmune RV-1730 — COVID booster — Phase 1
AstraZeneca AZD6563 — mRNA VLP COVID, Phase 1
Providence PTX-COVID19-B — COVID — Phase 1–2

VLPCOV-1 to VLPCOV-5 / VLPCOV-U-1 — VLP Therapeutics — saRNA COVID — Phase 3
Seqirus saRNA flu (HA + NA) — seasonal flu — Phase 1
RBI-4000 — Replicate Bioscience — saRNA rabies — Phase 1
~ Mary Talley Bowden MD